MedTrace Logo

The Potential of Robotic-Assisted Gait Training in a Rehabilitation Setting

NCT07529054 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-14

No results posted yet for this study

Summary

Robotic-assisted gait training (RAGT) devices, such as the Lokomat®, are commonly used to support gait rehabilitation by enabling repetitive, task-specific walking movements. The functional proprioceptive stimulation (FPS) device Vibramoov® represents a novel technology designed to stimulate proprioceptors at the muscle-tendon junction through targeted vibratory stimuli, thereby activating sensorimotor centers in the brain and potentially facilitating movement execution.

The aim of this randomized controlled trial is to investigate whether Lokomat® training combined with Vibramoov® leads to greater improvements in qualitative and quantitative gait parameters in stroke patients compared with Lokomat® training alone. The study will be conducted at the Gröbming Rehabilitation Center and will include patients undergoing a four-week neurological inpatient rehabilitation program. Participants will be randomly assigned to an intervention group (Lokomat® + Vibramoov®) or a control group (Lokomat® only), with 20 patients per group.

Primary outcomes include the 6-Minute Walk Test (6MWT) and spatiotemporal gait parameters. Additional assessments include functional scores, patient-reported outcome measures, and blood biomarkers. Statistical analyses will be performed depending on data distribution. A follow-up assessment evaluating EQ-5D and PHQ-4 will be conducted six months after completion of the rehabilitation program.

Conditions

  • Stroke
  • Robotic Assisted Gait Training
  • Vibration Therapy
  • Gait Biomechanics

Interventions

DEVICE

Lokomat + Vibramoov

The conventional Robotic Assisted Gait Training is combined with vibrational stimuli which is a novel approach.

DEVICE

Lokomat

Conventional Robotic Assisted Gait Training with the Lokomat

Sponsors & Collaborators

  • Reha-Zentrum Gröbming

    collaborator UNKNOWN

  • Ludwig Boltzmann Institute for Arthritis and Rehabilitation

    lead NETWORK

Principal Investigators

  • Bibiane Steinecker-Frohnwieser, Priv. Doz. Mag. Dr. · Ludwig Boltzmann Institut Arthritis und Rehabilitation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-05
Primary Completion
2027-02-28
Completion
2027-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07529054 on ClinicalTrials.gov